Ítem
Acceso Abierto

Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol

Mostrar el registro sencillo de la publicación
dc.creatorFeliciano-Alfonso, John E.spa
dc.creatorVargas-Villanueva, Andrésspa
dc.creatorMarín, María Alejandraspa
dc.creatorTriviño, Lauraspa
dc.creatorCarvajal, Nataliaspa
dc.creatorMoreno, Manuelaspa
dc.creatorLuna, Tatianaspa
dc.creatorLopez de Mesa, Claraspa
dc.creatorMuñoz-Ortiz, Julianaspa
dc.creatorde-la-Torre, Alejandraspa
dc.date.accessioned2020-05-26T00:01:24Z
dc.date.available2020-05-26T00:01:24Z
dc.date.created2019spa
dc.description.abstractBackground: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s).eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1186/s13643-019-1067-8
dc.identifier.issn20464053
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23361
dc.language.isoengspa
dc.publisherBioMed Central Ltd.spa
dc.relation.citationIssueNo. 1
dc.relation.citationTitleSystematic Reviews
dc.relation.citationVolumeVol. 8
dc.relation.ispartofSystematic Reviews, ISSN:20464053, Vol.8, No.1 (2019)spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85067883921&doi=10.1186%2fs13643-019-1067-8&partnerID=40&md5=2bd89c5ab5587fe47ba397b376f65979spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAntibiotic agentspa
dc.subject.keywordoculareng
dc.subject.keywordAtovaquonespa
dc.subject.keywordAzithromycinspa
dc.subject.keywordCiprofloxacinspa
dc.subject.keywordClarithromycinspa
dc.subject.keywordClindamycinspa
dc.subject.keywordCotrimoxazolespa
dc.subject.keywordDapsonespa
dc.subject.keywordDoxycyclinespa
dc.subject.keywordErythromycinspa
dc.subject.keywordLincomycinspa
dc.subject.keywordMacrolidespa
dc.subject.keywordMethotrexatespa
dc.subject.keywordMinocyclinespa
dc.subject.keywordMiokamycinspa
dc.subject.keywordNifurtimoxspa
dc.subject.keywordPyrimethaminespa
dc.subject.keywordRifabutinspa
dc.subject.keywordSpiramycinspa
dc.subject.keywordSulfadoxinespa
dc.subject.keywordSulfafurazolespa
dc.subject.keywordSulfamerazinespa
dc.subject.keywordSulfonamidespa
dc.subject.keywordTetracyclinespa
dc.subject.keywordBlurred visionspa
dc.subject.keywordChorioretinitisspa
dc.subject.keywordEye inflammationspa
dc.subject.keywordGenetic heterogeneityspa
dc.subject.keywordHumanspa
dc.subject.keywordIntraocular pressurespa
dc.subject.keywordLeukocyte countspa
dc.subject.keywordMeta analysisspa
dc.subject.keywordOcular toxoplasmosisspa
dc.subject.keywordOptic diskspa
dc.subject.keywordOutcome assessmentspa
dc.subject.keywordPriority journalspa
dc.subject.keywordQuality controlspa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordRecurrent diseasespa
dc.subject.keywordReviewspa
dc.subject.keywordSystematic reviewspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVisual impairmentspa
dc.subject.keywordAnti-bacterial agentsspa
dc.subject.keywordToxoplasmaspa
dc.subject.keywordToxoplasmosiseng
dc.subject.keywordUveitisspa
dc.titleAntibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocolspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
s13643-019-1067-8.pdf
Tamaño:
597.11 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos